Shares of ResMed Inc. (RMD), which have been pounded in recent weeks by concerns that the obesity-drug craze could hurt demand for the company's sleep therapy devices, are poised for a turnaround, according to Needham analysts. Although GLP-1 drugs, such as Novo Nordisk's (NOVO-B.KO) Ozempic and Wegovy, may cause some patients to stop using CPAP machines as their sleep apnea becomes less severe, "these impacts are likely to be small," the analysts wrote in a note Wednesday, saying that ResMed can sustain 5% to 7% revenue growth and double-digit per-share earnings growth for the next few years. The analysts raised their rating on ResMed shares to buy, from hold, and set a $180 price target for the stock. ResMed shares gained 1% premarket on Wednesday and have dropped 26% in the year to date, while the S&P 500 has gained 17%.
https://www.morningstar.com/news/marketwatch/20230906311/resmed-shares-can-overcome-obesity-drug-craze-analysts-say
- Forums
- ASX - By Stock
- weight loss & RMD ?
Shares of ResMed Inc. (RMD), which have been pounded in recent...
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RMD (ASX) to my watchlist
|
|||||
Last
$29.10 |
Change
0.320(1.11%) |
Mkt cap ! $18.47B |
Open | High | Low | Value | Volume |
$29.11 | $29.39 | $29.06 | $79.72M | 2.743M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1068 | $29.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$29.11 | 5546 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 29.100 |
1 | 523 | 29.090 |
1 | 137 | 29.080 |
1 | 689 | 29.050 |
1 | 102 | 29.010 |
Price($) | Vol. | No. |
---|---|---|
29.230 | 899 | 1 |
29.300 | 1087 | 2 |
29.350 | 330 | 1 |
29.380 | 979 | 2 |
29.390 | 1780 | 2 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
RMD (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online